Propanc Biopharma, Inc. Common Stock Total Assets
Propanc Biopharma, Inc. Common Stock total assets. Based on the latest financial reports, Propanc Biopharma, Inc. Common Stock (PPCB) holds total assets worth $12.78 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Propanc Biopharma, Inc. Common Stock for the company's overall valuation and market capitalisation.
Total Assets of Propanc Biopharma, Inc. Common Stock (2010–2026)
Total assets of Propanc Biopharma, Inc. Common Stock from 2010 to 2026. This chart illustrates how Propanc Biopharma, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See PPCB stock price for real-time trading data and today's change.
Propanc Biopharma, Inc. Common Stock - Asset Composition Analysis
Propanc Biopharma, Inc. Common Stock Total Assets Breakdown (June 2026)
Propanc Biopharma, Inc. Common Stock total assets breakdown as of June 2026. Propanc Biopharma, Inc. Common Stock's total assets of $12.78 Million consist of 66.8% current assets and 33.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 6.5% |
| Accounts Receivable | $13.69K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2010–2026)
This chart illustrates how Propanc Biopharma, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Propanc Biopharma, Inc. Common Stock short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Propanc Biopharma, Inc. Common Stock's current assets represent 66.8% of total assets in 2026, a decrease from 91.1% in 2010.
- Cash Position: Cash and equivalents constituted 6.5% of total assets in 2026, up from 1.2% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2010.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
Propanc Biopharma, Inc. Common Stock Competitors by Total Assets
Key competitors of Propanc Biopharma, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Propanc Biopharma, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.55 | 1.50 | 0.02 |
| Quick Ratio | 2.55 | 1.50 | 0.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.19 Million | $2.77 Million | $-2.31 Million |
Propanc Biopharma, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Propanc Biopharma, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.14 |
| Latest Market Cap to Assets Ratio | 0.36 |
| Asset Growth Rate (YoY) | -34.9% |
| Total Assets | $12.78 Million |
| Market Capitalization | $4.63 Million USD |
Valuation Analysis
Below Book Valuation: The market values Propanc Biopharma, Inc. Common Stock's assets below their book value (0.36x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Propanc Biopharma, Inc. Common Stock's assets decreased by 34.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Propanc Biopharma, Inc. Common Stock (2010–2026)
The table below shows the annual total assets of Propanc Biopharma, Inc. Common Stock from 2010 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-06-30 | $12.78 Million | -34.90% |
| 2025-06-30 | $19.63 Million | +27028.87% |
| 2024-06-30 | $72.36K | +19.95% |
| 2023-06-30 | $60.33K | -26.11% |
| 2022-06-30 | $81.65K | +523.24% |
| 2021-06-30 | $13.10K | -86.70% |
| 2020-06-30 | $98.52K | -3.08% |
| 2019-06-30 | $101.65K | +42.40% |
| 2018-06-30 | $71.39K | -24.91% |
| 2017-06-30 | $95.07K | -74.93% |
| 2016-06-30 | $379.14K | -39.54% |
| 2015-06-30 | $627.07K | +451.29% |
| 2014-06-30 | $113.75K | +6410.88% |
| 2013-06-30 | $1.75K | -96.22% |
| 2012-06-30 | $46.27K | -99.57% |
| 2011-06-30 | $10.81 Million | +24554.96% |
| 2010-06-30 | $43.86K | -- |
About Propanc Biopharma, Inc. Common Stock
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. Th… Read more